| Q3 2025 Revenue | $126.2M | CFO (prepared) |
| Q3 Non-GAAP Gross Margin | 44.1% | CFO (prepared) |
| Q3 Operating Expenses | $48M | CFO (prepared) — $2M lower than guidance |
| Q3 Capital Expenditures | $4M | CFO (prepared) — mainly facility improvements |
| Q3 Cash & Investments Change | -$11.2M | CFO (prepared) — driven by 17% sales growth & AR increase |
| Q3 AR Increase | $33M | CFO (prepared) |
| Q3 Net Interest Income | ~$1.1M | CFO (prepared) |
| Q3 Tax Provision | $11.7M | CFO (prepared) — $3.5M lower than forecast due to tax reserve reversal |
| Total Debt (Q3 end) | $18M | CFO (prepared) — unchanged QoQ |
| Q3 Test Cell Utilization | 74.5% | CEO (prepared) |
| Convertible Notes Gross Proceeds | $287.5M | CFO (prepared) — 1.5% interest, 32.5% conversion premium, 5-year term |
| 2025 HBM Inspection Revenue Forecast | $10M–$11M | CEO (prepared) |
| Q4 Revenue Guidance | ~$122M ± $7M | CFO (prepared) |
| Q4 Gross Margin Guidance | ~45% | CFO (prepared) |
| Q4 OpEx Guidance | ~$50M | CFO (prepared) |
| Q4 Net Interest Income Guidance | ~$1.7M | CFO (prepared) |
| Q4 Tax Provision Guidance | ~$4M | CFO (prepared) |
| Q4 Diluted Share Count Guidance | ~47.1M shares | CFO (prepared) |